Xolair (omalizumab): Drug Safety Communication - Slightly Elevated Risk of Cardiovascular and Cerebrovascular Serious Adverse Events

FDA approves label changes after review of a five year safety study.
Source: FDA MedWatch - Category: American Health Source Type: news